AI Integration for Philips IntelliSpace Discovery

AI integration for Philips IntelliSpace Discovery connects at three primary layers: the data ingestion pipeline (DICOMweb, HL7), the advanced visualization and analysis engine, and the research data repository. The goal is to intercept imaging studies destined for research cohorts, run automated AI analysis—such as tumor volumetry on longitudinal CTs or white matter lesion segmentation on brain MRIs—and write structured quantitative results (e.g., RECIST measurements, radiomic features) back as DICOM Structured Reports (SR) or directly into the platform's research database. This turns manual, expert-dependent measurement tasks into reproducible, batch-executable workflows.

Implementation typically uses a containerized AI inference service, deployed on-premises or in a compliant cloud, that listens to a DICOM Study Arrival event from IntelliSpace Discovery. Upon trigger, the service retrieves the study via DICOMweb, executes the model (e.g., a nnU-Net for organ segmentation), and posts results back. The key is configuring IntelliSpace Discovery's workflow manager to recognize these AI-generated outputs and make them available within the researcher's analysis workspace—seamlessly overlaying segmentations on the 3D viewer or populating a spreadsheet with extracted biomarkers for statistical analysis.

Governance is critical. Each AI-derived measurement must be traceable back to the model version, inference parameters, and original image data. Implement audit logging at the integration layer and establish a human review queue within IntelliSpace Discovery for a radiologist or researcher to validate AI outputs before they are locked into a trial dataset. Rollout should start with a single, high-value biomarker (e.g., liver fat fraction quantification) to validate the pipeline, then expand to a library of containerized models managed through a platform like the Philips AI Orchestrator, enabling researchers to self-serve analyses while maintaining HIPAA-compliant data governance. For a deeper look at enterprise-scale deployment, see our guide on AI Integration for Clinical Trials and Research PACS.

Integration with IntelliSpace Discovery focuses on three primary surfaces: the Research Worklist, the Advanced Visualization Toolkit, and the Quantitative Analysis Engine. AI models are deployed as containerized microservices, typically on a secure cloud or on-premises Kubernetes cluster, and communicate via RESTful APIs and DICOMweb. The workflow begins when a researcher selects a cohort of imaging studies (e.g., a clinical trial arm) within Discovery. A secure DICOMweb query retrieves the anonymized studies from the connected Universal Data Manager (UDM) or PACS VNA and pushes them to a dedicated, encrypted ingestion queue. From there, a workflow orchestrator (like Apache Airflow or a custom service) triggers the appropriate AI inference pipeline—for tasks like automated tumor segmentation, radiomic feature extraction, or longitudinal change analysis—and returns structured results (DICOM SR or JSON) back to Discovery's database for visualization.

Security and governance are architected at every layer. All data in transit uses TLS 1.3, and data at rest is encrypted. The AI inference environment operates within a HIPAA-aligned virtual private cloud, with strict network policies isolating the AI services from the core clinical PACS. Access is controlled via role-based access (RBAC) mapped to Discovery's user groups, ensuring only authorized researchers can trigger AI jobs or view results. Every AI inference is logged with a full audit trail, capturing the user, input data hash, model version, parameters, and output for reproducibility and compliance. For sensitive research, a human-in-the-loop review step can be configured in the workflow, where AI-generated segmentations or measurements are presented in the Discovery viewer for researcher verification and adjustment before finalizing the analysis.

Rollout follows a phased, study-specific approach. We recommend starting with a single, high-value research workflow—such as automated volumetric response assessment in oncology trials—within a sandbox Discovery environment. This allows validation of the data pipeline, AI model performance on your institution's data, and researcher feedback on the integrated UI. Successful pilots are then scaled by defining reusable AI "modules" in Discovery's toolkit, enabling researchers to self-serve common analyses while IT maintains governance over the underlying model versions and infrastructure costs. This architecture ensures AI augments the exploratory power of IntelliSpace Discovery without compromising the security, integrity, or compliance of the underlying imaging data.

Integrating AI into Philips IntelliSpace Discovery for research workflows touches sensitive, often de-identified but still regulated, patient imaging data. The architecture must enforce strict role-based access control (RBAC) tied to the platform's user management, ensuring only authorized researchers can trigger AI inference on specific projects or cohorts. All AI-generated outputs—such as quantitative biomarkers, segmentation masks, or analysis reports—must be written back as DICOM Structured Reports (SR) or annotated datasets within the Discovery environment, creating a permanent, auditable link between the source image, the AI model version, and the derived research data. This traceability is critical for study reproducibility and audit trails.

A phased rollout mitigates risk and builds user trust. Start with a pilot cohort in a single research domain (e.g., oncology tumor volumetrics). Configure the integration to run AI models in a 'shadow mode' initially, where results are generated and stored but not yet visible in the primary researcher workflow. This allows for validation against ground truth and calibration of confidence thresholds. The next phase introduces assistive overlays, where AI-generated segmentations or measurements are presented as suggestions within the IntelliSpace Discovery advanced visualization tools, requiring researcher confirmation. The final phase enables automated batch processing for approved, high-confidence workflows, dramatically accelerating analysis for large-scale retrospective studies or clinical trial screening.

Governance extends to the AI models themselves. Implement a model registry to track versions, training data provenance, and validation performance metrics. Integrate this registry with IntelliSpace Discovery's project management features, so researchers can see exactly which model was used for each analysis. For studies intended to support regulatory submissions, the entire pipeline—from DICOM retrieval via the Universal Data Manager API, to inference, to result storage—must be validated under a GxP-compliant framework. This controlled, phased approach ensures AI augments research velocity without compromising the scientific rigor or compliance posture of the institution.